MSD Pharma gets CDSCO panel nod for New Indications of Pembrolizumab in India
New Delhi: The Subject Expert Committee functioning under the Central Drugs Standard Control Organization (CDSCO) has granted approval for additional indications of Pembrolizumab (Keytruda) Injection 100 mg/4 ml, manufactured by MSD Pharmaceuticals, expanding its use for advanced cancers in India. However, the nod came with a condition that the firm should conduct a Phase IV […]
